Clinical trial
Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio…
NCT00160082 · Calliditas Therapeutics AB, Industry · Completed
Key facts
| NCT number | NCT00160082 |
|---|---|
| Title | Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS) |
| Official title | Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS): A Randomized, Two-Arm, Parallel, Double-Blind, Multi-Centre, Placebo Controlled Study |
| Lead sponsor | Calliditas Therapeutics AB, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Post Polio Syndrome, PPS |
| Intervention type | Drug |
| Interventions | Xepol |
| Enrollment | 124 |
| Start date | Jan 1, 2001 |
| Completion | May 1, 2003 |
| First posted | Sep 12, 2005 |
| Last update posted | Apr 3, 2007 |
| Countries | Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: